Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone

Inclusion Criteria: * Subjects with schizophrenia or another psychotic disorder according to DSM IV criteria who requires long term antipsychotic therapy * Currently treated with either an atypical antipsychotic, other than risperidone, a conventional depot antipsychotic or oral conventional antipsychotic * Subject has been symptomatically stable on a stable dose of an antipsychotic the last month * Subject and/or patient's relative, guardian or legal representative has signed the informed consent form Exclusion Criteria: * First antipsychotic treatment ever * On clozapine during the last 3 month * Serious unstable medical condition * History or current symptoms of tardive dyskinesia * History of neuroleptic malignant syndrome * Pregnant or breast-feeding female * Female patient of childbearing potential without adequate contraception. * Participation in an investigational drug trial in the 30 days prior to selection * Known intolerance/non-responder to risperidone